PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's

University College London Hospitals (Other)
Overall Status
CT.gov ID
Cure Parkinson's (Other)

Study Details

Study Description

Brief Summary

PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies.

    Once the questionnaire is completed, the participant is sent a saliva collection kit in the post to provide a sample for genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.

    Once tested, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    4800 participants
    Observational Model:
    Time Perspective:
    Official Title:
    PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
    Actual Study Start Date :
    Feb 15, 2020
    Anticipated Primary Completion Date :
    Feb 14, 2025
    Anticipated Study Completion Date :
    Aug 20, 2040

    Outcome Measures

    Primary Outcome Measures

    1. Genotype of participants [20 years]

      The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    Inclusion Criteria:
    • Formal diagnosis of Parkinson Disease
    Exclusion Criteria:
    • Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.

    • History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)

    • Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.

    • Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).

    Contacts and Locations


    Site City State Country Postal Code
    1 University College London (UCL) London United Kingdom NW3 2PF

    Sponsors and Collaborators

    • University College London Hospitals
    • Cure Parkinson's


    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Anthony Schapira, Professor Anthony Schapira, University College London Hospitals
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • 173275
    First Posted:
    Nov 30, 2023
    Last Update Posted:
    Nov 30, 2023
    Last Verified:
    Nov 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 30, 2023